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Abstract: Many experimental studies indicate that some antiepileptic drugs possess neuroprotective properties
in varied models of neuronal injury. Levetiracetam is a second-generation antiepileptic drug with a novel mecha-
nism of action. In the present study, we evaluated the putative neuroprotective effect of levetiracetam on prima-
ry hippocampal cultures at seven day in vitro. Cell death was induced by incubation of neural cultures in hypoxic
conditions over 24 hours. Neuronal injury was assessed by morphometric investigation of death/total ratio of
neurons in light microscopy using Trypan blue staining and by evaluation of lactate dehydrogenase (LDH) re-
lease in the culture medium. Our results indicate that pre-conditioning of hippocampal cultures with high con-
centrations of levetiracetam (100 mM and 300 mM) protects neurons against hypoxia-induced death. Two-fold
higher number of neurons remained viable as compared to control cultures without drug. Lack of neuroprotec-
tive action of the drug on hippocampal neural cultures was observed, when a low concentration (10 mM) of
levetiracetam was used. (Folia Histochemica et Cytobiologica 2011, Vol. 49, No. 1, 148–152)
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Introduction
Disturbances to the function of the central nervous
system, occurring both acutely and chronically, acti-
vate the cascade of complex biochemical processes,
which lead to degeneration and finally to the death
of neurons [1]. A classical example from clinical
practice could be an ischemic stroke, triggered by
an occlusion of cerebral artery. A deep energetic
deficit severely disturbs the functions of cellular and
mitochondrial enzymes and imbalances the ion sys-
tem. Degeneration of the neurons is probably trig-
gered by excessive Ca2+ influx, additionally ampli-
fied by Ca2+ efflux from the endoplasmic reticulum [2].
Increased intracellular concentration of Ca2+ results
in rapid efflux of glutamate to the synapse, and
glutamate-mediated neurotoxicity [3, 4]. Sustained
elevation in Ca2+ is assumed to set in motion var-
ious pathological processes, which could degenerate
neurons by activating proteases, lipases, endonu-
cleases, pro-apoptotic genes and nitric oxide syntha-
ses and by promoting the formation of free oxygen
radicals [5, 6].
There are known to be two pathways of neural
death: necrosis and apoptosis. Recent research indi-
cates that these processes coincide and can be termed
‘aponecrosis’ [7, 8]. Recent decades have seen many
scientific reports about the putative neuroprotective
effects of various drugs and chemical compounds. Neu-
roprotectants stop or delay various stages of the com-
plex mechanism of neuronal death. Neuronal cultures
are often used as an in vitro model to assess the effects
of various chemical compounds in the field of neuro-
protection [9]. Hippocampal or cortical neurons are
usually preferred because these neurons are selective-
ly vulnerable to the effects of hypoxia and ischemia,
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both in vivo and in vitro [10]. Because of their complex,
multidirectional mechanism of action, some traditio-
nal, and some new, antiepileptic drugs have been
suggested as promising neuroprotectants, and have
been studied in neuronal cultures, in which varied cell
death-inducible factors have been used [11, 12].
Levetiracetam (LEV), the a-ethyl analogue of the
nootropic piracetam, is a relatively new antiepileptic
drug, with a unique chemical structure and mecha-
nism of action. LEV has a very favorable pharmaco-
kinetic profile: excellent bioavailability, linear kine-
tics, minimal plasma protein binding, and quick
achievement of steady state concentrations [13]. LEV
is widely used for protection against partial seizures,
and is also effective in the treatment of primary gene-
ralized seizures [14].
The mechanism of action of LEV is distinct from
first-generation and other second-generation AEDs.
LEV appears not to work by the three classic routes
of other AEDs: sodium channel modulation, low-volt
-age-activated (T-type) calcium channel modulation,
and gamma-aminobutyric acid (GABA) facilitation.
LEV’s mode of action is not fully elucidated, but it
has been found to target high-voltage, N-type calc-
ium channels [15] as well as the synaptic vesicle pro-
tein 2A (SV2A). The drug binds reversibly and spe-
cifically to this plasma membrane protein receptor
site [16, 17]. The functional role of SV2A is not well
understood, but it seems to be a positive modulator
of synaptic transmission that may act by preparing
vesicles for fusion [18]. We decided to undertake our
study because the scientific reports discussing the
putative neuroprotective action of LEV are both
scarce and controversial, especially as regards neu-
ronal cultures.
Material and methods
Culture of hippocampal neurons
Primary cultures of hippocampal neurons were pre-
pared from embryonic day 18 Sprague–Dawley rats
following Brewer et al. [19] and Brewer and Price [20].
Dissected hippocampi were purchased commercially
and delivered in B27/Hibernate E from Brain Bits
(http://www.BrainBitsLLC.com). Tissues were incu-
bated with papain (Worthington) in Hibernate E me-
dium (BrainBits) at 30°C for 20 minutes, followed by
mechanical trituration with a fire-polished Pasteur pi-
pette. The mixture was transferred into B27/Hiber-
nate E medium and the cells were centrifuged at 200
× g for one minute. The supernatant was quickly as-
pirated, and the cells were re-suspended in 1 mL of
B27/neurobasal medium (invitrogen) with 0.5 mM 
glutamax and 25 mM glutamate. Once in suspension,
the number of viable cells was determined by Trypan
blue exclusion using a hemacytometer.
Next, cells were plated on 24-well plates coated
with poly-D-lysine (Becton Dickinson) at a density
of 32 × 103 cells/2 cm2. Cultures were grown in a hu-
midified incubator at 37°C, 5% CO2, 9% O2. Half of
the medium was replaced with NbActiv4 medium
(BrainBits) every three days. Under these conditions,
cell cultures comprise more than 95% neurons [19,
21]. The experiment was performed after seven days
in culture.
Drug preparation
Levetiracetam was supplied from Sigma-Aldrich and
dissolved in NbActiv4 medium (BrainBits) at a con-
centration of 1 mM as a stock solution. The solution
was further diluted with the same medium to obtain
desired concentrations.
Hypoxia in culture
Before starting exposure of the cultured neurons to
hypoxia, the medium was replaced with fresh NbAc-
tiv4 medium with 10 mM, 100 mM or 300 mM leveti-
racetam. Control cultures were grown without leveti-
racetam. Cultures were then transferred into an in-
cubator at normoxic conditions for two hours. Next,
cultures (except control) were replaced into an incu-
bator set up for a hypoxia experiment. Hypoxia was
maintained by flushing the incubator with 20% CO2
which resulted in a reduction of the oxygen concen-
tration in the incubator atmosphere to less than 1%.
Cultures were exposed to hypoxia or normoxia (con-
trol) for 24 hours.
Morphometric study of neuronal cell survival
After cessation of hypoxia, neuronal cultures were
stained with 0.4% Trypan blue (Sigma-Aldrich). Un-
stained cells were regarded as viable, and stained cells
were regarded as dead. Total cell number, and num-
ber of Trypan blue positive cells (death cells), were
counted via a light microscope under magnification
× 200 by an independent, blinded investigator. For each
condition, five non-overlapping fields of three different
wells (i.e. 15 fields per condition) were analyzed.
Evaluation of cell death by LDH assay
Neural injury was evaluated additionally by measuring
lactate dehydrogenase (LDH) activity released in the
media 24 hours after hypoxia cessation using the colo-
rimetric assay (Roche). The experiment was performed
as per the manufacturer’s instructions. The intensity
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of red color formed in the assay and measured at
a wavelength of 490 nm was proportional to LDH ac-
tivity and to the number of damaged cells. Data were
normalized to the activity of LDH released from con-
trol culture media (100%) and expressed as a percent-
age of the control. The experiment was performed three
times with three wells per condition each time.
Data analysis
Data after normalization as a percentage of control ±
± SEM were analyzed using Statistica software. One-
way analysis of variance (ANOVA) was used to deter-
mine overall significance. Differences between control
and experimental groups were assessed with post hoc
Tukey test, with the significant differences marked in
the following way: *p < 0.01 and **p < 0.001 (vs. con-
trol cultures), #p < 0.001 (vs. 20% CO2 treated cul-
tures). Data were expressed as means ± SD. A level of
p < 0.05 was considered statistically significant.
Results
Morphometric findings
The percentage of dead nerve cells after seven days
in dissociated culture in normoxic conditions was
about 6%, and it did not differ statistically among
individual plates of cultures with different concen-
trations of LEV. 24-hour oxidative stress caused
death of over a quarter of the population of neu-
rons in control cultures without LEV and in the cul-
ture with a low, 10 mM, concentration of the antie-
pileptic drug (p < 0.001). In cultures with a high
concentration of LEV, (100 mM and 300 mM), the
percentage of dead cells was 16% and 13%, respec-
tively (Figure 1).
Measurement of lactate dehydrogenase (LDH)
activity
In biochemical assessment of LDH efflux from disin-
tegrating neurons to the culture media, we found sta-
tistically significant 40% and 46% decreases of LDH
concentration in cultures concerning 100 mM and 300
mM of LEV, respectively, compared to a control cul-
ture without the drug (p < 0.001). The activity of LDH
in dishes concerning 10 mM concentration of LEV
was comparable to the control (Figure 2).
Discussion
Numerous reports have suggested that conventional,
as well as recently introduced, antiepileptic drugs have
some neuroprotective activity in the experimental
models of hypoxic/ischemic brain injury [11, 22, 23].
The neuroprotective activity of certain antiepileptic
drugs seems to be connected to their complex mecha-
nisms of action. The commonest actions were shown
on ion channels, GABA-ergic and glutamatergic me-
tabolism, receptors or secondary messengers [24].
Those biochemical mechanisms are connected tight-
ly with necrosis/apoptosis pathways in the neurons.
Modulation of these processes by mostly antiepile-
ptic drugs results in inhibition or limitation of them,
otherwise neuroprotection.
The trials of a new generation of antiepileptic drugs
seem to be of great interest from a practical point of
view. Newer antiepileptic drugs, when compared to
Figure 1. The effect of levetiracetam (10 mM, 100 mM and
300 mM) on hypoxia-induced  neuronal injury. Cultures were
treated with levetiracetam for 26 h and Trypan blue staining
was applied. Each bar represents a mean percentage ± SD
of death neurons. *p < 0.01; **p < 0.001 vs. control cells in
normoxic conditions;  #p < 0.001 vs. control cells in hypoxic
condition, respectively
Figure 2. The effect of levetiracetam  (10 mM, 100 mM
and 300 mM) on LDH activity 24 h after cessation of
hypoxia-induced injury. Each bar represents a mean
percentage ± SD of LDH activity in culture medium
when compared to the LDH activity in control culture
without LEV. *p < 0.001 vs. control
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conventional drugs, have equal or greater efficacy, but
fewer toxic effects and better tolerability [25].
The results of our study indicate that none of the
three concentrations of LEV used in the experiment
exerted per se a toxic effect on neuronal cultures.
There were no statistically significant differences bet-
ween cultures in morphometric and LDH activity as-
sessment in normoxic conditions.
LEV, when used in higher concentrations, has
a beneficial neuroprotective effect on hippocampal
neurons in culture after hypoxia-induced injury. In
cultures with a concentration of LEV of 100 µM and
300 µM, an increased survival of nerve cells in the
morphometric evaluation was noted, of 47% and 59%,
respectively. Comparable neuroprotective effects of
the drug have been confirmed by assessing LDH ac-
tivity in the culture medium.
Our results indicate that higher concentrations of
LEV protect at least half of hippocampal neurons in
culture, when compared to non-treated cultures.
Published reports looking at the neuroprotective
actions of LEV are scarce, controversial and have
been performed mostly as experimental in vitro stu-
dies. Hanon and Klitgaard [26] demonstrated the neu-
roprotective properties of LEV in the experimental
model of ischemic stroke triggered by occlusion of
medial cerebral artery. When a high dose of LEV was
applied to the rats i.p. before artery occlusion, the
insult area was about 33% smaller. Promising neuro-
protective effects of LEV have also been observed in
murine models of closed head injury and subarach-
noid hemorrhage [27]. In experimental models of
kainic acid-induced neurotoxicity, the results were
controversial. Marini et al. found a neuroprotective
effect of LEV in hippocampal neuronal cultures [28],
while Kitano et al. observed a similarly beneficial ef-
fect only when the n-propyl analogue of LEV, nefirac-
etam, was used rather than LEV itself [29]. The neu-
roprotective properties of LEV have also been ob-
served in animal models of an electrically-induced
epileptic state. This effect could be seen by the posi-
tive influence of the drug on the efficiency of ener-
getic processes of neurons in mitochondria [30].
Custer et al. found a reduction of excitatory synaptic
potential responses in hippocampal neuron cultures
from mice in which SV2A had been deleted by gene
targeting [18].
Published data evaluating the neuroprotective ef-
fect of LEV in vitro are inconclusive. There has been
found to be no protective effect of LEV on neurons
in hypoglycemia and hypoxia-induced damage of or-
ganotypic hippocampal culture. But some other anti-
epileptic drugs did have a protective effect [31]. We
have not found in the literature any studies concer-
ning the potential neuroprotective effects of LEV
in dissociated cultures of hippocampal neurons. Stu-
dies in neuron cultures have focused on efforts to
explain the mechanisms of LEV action which have
a putative neuroprotective effect. Some studies have
confirmed that LEV inhibits ryanodine and IP3 re-
ceptors in hippocampal culture [32]. These receptors
are responsible for excessive accumulation of Ca2+ in
the cytoplasma of neurons. This is an important stage
in the process of cell death [32]. Another experiment
found that LEV modulates AMPA receptors in corti-
cal neuronal cultures and leads to impairment of
postsynaptic potential in these cells [33]. Angehagen
et al. reported that LEV inhibits the caffeine-induced
and Ca2+-dependent epileptiform discharges in hip-
pocampal neuronal culture [34]. This drug also in-
hibits high potential-dependent calcium channels in
conditions in vitro [35]. No effect of LEV on Na+ and
T-type Ca2+ currents has been found [36]. Cardile et
al. found that LEV enhances brain-derived neu-
rotrophic factor expression in astrocytes culture [37],
which is the next neuroprotective mechanism of ac-
tion of this drug.
With respect to action mechanisms, LEV is dis-
tinct from traditional antiepileptic drugs such as Na+
channel blockers, GABA enhancers and T-type Ca2+
channel blockers. Previous data have demonstrated
that mechanisms of LEV action have a near con-
nection with the excitotoxic pathway of neuronal
death, which is triggered by hypoxia. The results of
our study confirmed also this neuroprotective effect
of LEV.
Conclusions
This experimental study demonstrates that a second-
-generation antiepileptic, levetiracetam, can prevent
hypoxia-inducible neuronal injury in cultured hippo-
campal neurons. The drug exerts neuroprotective ef-
fects only when used in higher concentrations in the
culture medium: 100 mM and 300 mM. Such concen-
trations of LEV caused that two-fold higher number
of neurons remained viable as compared to control
cultures without drug.
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